Effect of sitagliptin combined with rosiglitazone on glucose and lipid metabolism as well as insulin resistance in patients with type 2 diabetes

Objective To observe the clinical efficacy of sitagliptin combined with rosiglitazone in treatment of patients with type 2 diabetes. Methods Totally 85 patients with type 2 diabetes were divided into control group(treated with routine treatment and rosiglitazone, n=42)and observation group(treated with routine treatment, rosiglitazone and sitagliptin, n=43), and both groups were treated for 2 months. Levels of fasting blood glucose, 2 h postprandial blood glucose, total cholesterol and triglyceride as well as insulin resistance index were compared between the two groups before treatment and after 2 months of treatment. Results After treatment, the levels of fasting blood glucose, 2 h postprandial blood glucose, total cholesterol and triglycerides in both groups were significantly lower than those before treatment, and the levels of indexes mentioned above in the observation group were significantly lower than those in the control group(P<0.05). After treatment, the insulin resistance index of the observation group was(4.06±0.97), which was significantly lower than(5.02±1.04)of the control group(P<0.05). Conclusion Sitagliptin combined with rosiglitazone is safe and effective in the treatment of patients with type 2 diabetes, which can reduce blood glucose and lipid levels and relieve insulin resistance.